Your browser doesn't support javascript.
loading
ONECUT2 is a driver of neuroendocrine prostate cancer.
Guo, Haiyang; Ci, Xinpei; Ahmed, Musaddeque; Hua, Junjie Tony; Soares, Fraser; Lin, Dong; Puca, Loredana; Vosoughi, Aram; Xue, Hui; Li, Estelle; Su, Peiran; Chen, Sujun; Nguyen, Tran; Liang, Yi; Zhang, Yuzhe; Xu, Xin; Xu, Jing; Sheahan, Anjali V; Ba-Alawi, Wail; Zhang, Si; Mahamud, Osman; Vellanki, Ravi N; Gleave, Martin; Bristow, Robert G; Haibe-Kains, Benjamin; Poirier, John T; Rudin, Charles M; Tsao, Ming-Sound; Wouters, Bradly G; Fazli, Ladan; Feng, Felix Y; Ellis, Leigh; van der Kwast, Theo; Berlin, Alejandro; Koritzinsky, Marianne; Boutros, Paul C; Zoubeidi, Amina; Beltran, Himisha; Wang, Yuzhuo; He, Housheng Hansen.
  • Guo H; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada. allen100006@gmail.com.
  • Ci X; The Vancouver Prostate Centre, Vancouver General Hospital and Department of Urologic Sciences, The University of British Columbia, Vancouver, V6H 3Z6, BC, Canada.
  • Ahmed M; Department of Experimental Therapeutics, BC Cancer Research Centre, Vancouver, V5Z 1L3, BC, Canada.
  • Hua JT; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.
  • Soares F; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.
  • Lin D; Department of Medical Biophysics, University of Toronto, Toronto, M5G 2M9, ON, Canada.
  • Puca L; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.
  • Vosoughi A; The Vancouver Prostate Centre, Vancouver General Hospital and Department of Urologic Sciences, The University of British Columbia, Vancouver, V6H 3Z6, BC, Canada.
  • Xue H; Department of Experimental Therapeutics, BC Cancer Research Centre, Vancouver, V5Z 1L3, BC, Canada.
  • Li E; Weill Cornell Medicine, New York, NY, 10065, USA.
  • Su P; Weill Cornell Medicine, New York, NY, 10065, USA.
  • Chen S; The Vancouver Prostate Centre, Vancouver General Hospital and Department of Urologic Sciences, The University of British Columbia, Vancouver, V6H 3Z6, BC, Canada.
  • Nguyen T; Department of Experimental Therapeutics, BC Cancer Research Centre, Vancouver, V5Z 1L3, BC, Canada.
  • Liang Y; The Vancouver Prostate Centre, Vancouver General Hospital and Department of Urologic Sciences, The University of British Columbia, Vancouver, V6H 3Z6, BC, Canada.
  • Zhang Y; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.
  • Xu X; Department of Medical Biophysics, University of Toronto, Toronto, M5G 2M9, ON, Canada.
  • Xu J; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.
  • Sheahan AV; Department of Medical Biophysics, University of Toronto, Toronto, M5G 2M9, ON, Canada.
  • Ba-Alawi W; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.
  • Zhang S; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.
  • Mahamud O; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.
  • Vellanki RN; College of Life Sciences, Central China Normal University, Wuhan, 430079, Hubei, People's Republic of China.
  • Gleave M; College of Basic Medical Sciences, Dali University, Dali, 671000, Yunnan, People's Republic of China.
  • Bristow RG; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.
  • Haibe-Kains B; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.
  • Poirier JT; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Rudin CM; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.
  • Tsao MS; Department of Medical Biophysics, University of Toronto, Toronto, M5G 2M9, ON, Canada.
  • Wouters BG; Department of Experimental Therapeutics, BC Cancer Research Centre, Vancouver, V5Z 1L3, BC, Canada.
  • Fazli L; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.
  • Feng FY; Department of Medical Biophysics, University of Toronto, Toronto, M5G 2M9, ON, Canada.
  • Ellis L; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.
  • van der Kwast T; The Vancouver Prostate Centre, Vancouver General Hospital and Department of Urologic Sciences, The University of British Columbia, Vancouver, V6H 3Z6, BC, Canada.
  • Berlin A; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.
  • Koritzinsky M; Department of Medical Biophysics, University of Toronto, Toronto, M5G 2M9, ON, Canada.
  • Boutros PC; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.
  • Zoubeidi A; Department of Medical Biophysics, University of Toronto, Toronto, M5G 2M9, ON, Canada.
  • Beltran H; Department of Computer Science, University of Toronto, Toronto, M5T 3A1, ON, Canada.
  • Wang Y; Ontario Institute for Cancer Research, Toronto, M5G 0A3, ON, Canada.
  • He HH; Vector Institute, Toronto, M5G 1M1, ON, Canada.
Nat Commun ; 10(1): 278, 2019 01 17.
Article en En | MEDLINE | ID: mdl-30655535
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Factores de Transcripción / Regulación Neoplásica de la Expresión Génica / Tumores Neuroendocrinos / Proteínas de Homeodominio / Proteína smad3 Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Factores de Transcripción / Regulación Neoplásica de la Expresión Génica / Tumores Neuroendocrinos / Proteínas de Homeodominio / Proteína smad3 Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Año: 2019 Tipo del documento: Article